<DOC>
	<DOCNO>NCT00452439</DOCNO>
	<brief_summary>The goal clinical research study learn Actonel ( risedronate ) help prevent development osteoporosis ( brittle weak bone ) cause steroid medication use treat leukemia . The safety treatment patient ALL LL also study .</brief_summary>
	<brief_title>A Study Actonel Prevention Bone Loss</brief_title>
	<detailed_description>One side effect use high dose corticosteroid treatment ALL osteoporosis . Risedronate medication design help prevent osteoporosis ( brittle weak bone ) . Before treatment receive complete physical exam . You around 1 tablespoon blood drawn blood test ( test addition routine blood test part treatment leukemia ) . You urine sample collect routine test . You also bone mineral density test . This test measure density bone spine , hip , total body . The test similar x-ray bone take . You randomly assign ( toss coin ) one two treatment group . Participants first group give risedronate ( per week ) , vitamin D ( per day ) , calcium ( per day ) . All three medication pills take mouth . Participants second group give placebo ( per week ) , vitamin D ( per day ) , calcium ( per day ) . All three medication pills take mouth . A placebo substance look like study drug active ingredient . Neither doctor know group assign . However , need care , information give doctor . Participants group continue receive chemotherapy study schedule . During chemotherapy , around 1 tablespoon blood drawn every 1-2 week routine blood test ( part standard care treatment leukemia ) . For study , urine sample collect repeat bone mineral density test 6 month , 12 month , 18 month , 24 month start study drug ( placebo ) . If develop intolerable side effect risedronate take study . This investigational study . Risedronate FDA approve commercially available . Up 80 eligible patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>1 . Age great equal 18 year 2 . Newly diagnose ALL LL receive chemotherapy augment BFM , HyperCVAD variant hyperCVAD . 3 . Female patient childbearing potential ( i.e . hysterectomy , loss menses 12 consecutive month ) , must willing use contraception . 4 . Negative pregnancy test female patient . 5 . Patients must enrol within 6 week start induction chemotherapy . 1 . Hypocalcemia le 8.4 ( correct account albumin level , [ see Appendix E formula ] ) 2 . Hypersensitivity risedronate bisphosphonates 3 . Inability sit stand upright least 30 minute 4 . Bone density Tscore 2.5 S.D less . 5 . Renal insufficiency ( calculated creatinine clearance &lt; 30cc/min , [ see Appendix F formula ] ) 6 . Patients 25hydroxyvitamin D concentration le 20 ng/ml evidence osteomalacia ( low ionize calcium high intact PTH ) . 7 . Concomitant use bisphosphonates , calcitonin , anabolic steroid , fluoride . 8 . Corrected calcium 10.2 , due cause relate leukemia/lymphoma ( i.e . hyperparathyroidism , multiple myeloma ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Acute Lymphocytic Leukemia</keyword>
	<keyword>Lymphoblastic Lymphoma</keyword>
	<keyword>Actonel</keyword>
	<keyword>Risedronate</keyword>
	<keyword>Bone Loss</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>